Prosemble Therapeutics

Prosemble Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs that modulate protein-protein interactions (PPIs). By leveraging its proprietary platform, the company identifies molecules that can either stabilize or disrupt specific protein assemblies to treat diseases previously considered undruggable. The company's approach aims to expand the reach of small molecule therapeutics into complex biological pathways involved in oncology and other therapeutic areas. Founded by Dr. Peter S. Kim, former President of Merck Research Laboratories, Prosemble is currently in the pre-clinical stage of development. The company is backed by prominent life science investors and is headquartered in the biotech hub of South San Francisco.